Sarcoma care in the era of precision medicine
Journal of Internal Medicine · 2023
DOI: 10.1111/joim.13717 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Internal Medicine, 2023. Verfasst von Karin Wallander und 6 weiteren Autor:innen. Beteiligte Einrichtung: Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden. Hauptthemen laut MEDLINE: Sarcoma, Sarcoma, Synovial, Soft Tissue Neoplasms. Die Arbeit wurde bisher 31-mal zitiert (Crossref) und nennt 166 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Wellcome Trust, Svenska Sällskapet för Medicinsk Forskning, Cancerfonden.
Abstract (Originalsprache)
Sarcoma subtype classification is currently mainly based upon histopathological morphology. Molecular analyses have emerged as an efficient addition to the diagnostic workup and sarcoma care. Knowledge about the sarcoma genome increases, and genetic events that can either support a histopathological diagnosis or suggest a differential diagnosis are identified, as well as novel therapeutic targets. In this review, we present diagnostic, therapeutic, and prognostic molecular markers that are, or might soon be, used clinically. For sarcoma diagnostics, there are specific fusions highly supportive or pathognomonic for a diagnostic entity—for instance, SYT :: SSX in synovial sarcoma. Complex karyotypes also give diagnostic information—for example, supporting dedifferentiation rather than low‐grade central osteosarcoma or well‐differentiated liposarcoma when detected in combination with MDM2 / CDK4 amplification. Molecular treatment predictive sarcoma markers are available for gastrointestinal stromal tumor (GIST) and locally aggressive benign mesenchymal tumors. The molecular prognostic markers for sarcomas in clinical practice are few. For solitary fibrous tumor, the type of NAB2 :: STAT6 fusion is associated with the outcome, and the KIT / PDGFRA pathogenic variant in GISTs can give prognostic information. With the exploding availability of sequencing technologies, it becomes increasingly important to understand the strengths and limitations of those methods and their context in sarcoma diagnostics. It is reasonable to believe that most sarcoma treatment centers will increase the use of massive‐parallel sequencing soon. We conclude that the context in which the genetic findings are interpreted is of importance, and the interpretation of genomic findings requires considering tumor histomorphology.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.
- Department of Oncology, Oslo University Hospital, Oslo, Norway.
- Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden.
- Department of Breast Cancer, Endocrine Tumors and Sarcoma, Karolinska University Hospital and Karolinska Comprehensive Cancer Centre, Stockholm, Sweden.
- Department of Pathology and Cancer diagnostics, Karolinska University Hospital, Stockholm, Sweden.
ORCID-Profile: Karin Wallander
Förderung
- Wellcome Trust
- Svenska Sällskapet för Medicinsk Forskning
- Cancerfonden
Zitieren
APA
Wallander, K., Öfverholm, I., Boye, K., Tsagkozis, P., Papakonstantinou, A., Lin, Y., & Haglund de Flon, F. (2023). Sarcoma care in the era of precision medicine. Journal of Internal Medicine. https://doi.org/10.1111/joim.13717
Vancouver
Wallander K, Öfverholm I, Boye K, Tsagkozis P, Papakonstantinou A, Lin Y, et al. Sarcoma care in the era of precision medicine. Journal of Internal Medicine. 2023. doi:10.1111/joim.13717
BibTeX
@article{Wallander2023,
author = {Wallander, Karin and Öfverholm, Ingegerd and Boye, Kjetil and Tsagkozis, Panagiotis and Papakonstantinou, Andri and Lin, Yingbo and Haglund de Flon, Felix},
title = {Sarcoma care in the era of precision medicine},
journal = {Journal of Internal Medicine},
year = {2023},
doi = {10.1111/joim.13717}
}
EUVIMED